Dr.Mukesh Verma
We are highly privileged to have Dr. Mukesh Verma as one of our advisors in
Genome India International, while we honor him as a member spotlight for this
month.
Dr. Mukesh Verma comes to the AERB (Analytic Epidemiology Research Branch)
from NCI’s Division of Cancer Prevention (DCP) where he was a Program Director
providing direction in the areas of biomarkers, early detection, risk assessment
and prevention of cancer, and cancers associated with infectious agents. He also
was Coordinator of DCP’s Small Business Programs (SBIR/STTR Programs). Dr. Verma
has developed concepts (PA and RFA) on exfoliated cells and circulating DNA and
their application in cancer detection and risk assessment. He also served as the
Project Officer for an Inter Agency Agreement with CDC with focus on biomarkers
of cervical cancer. Mukesh holds a M.Sc. from Pantnagar University and a Ph.D.
in the field of host-virus interaction from Banaras Hindu University. He did
postdoctoral research at George Washington University and was the first to
demonstrate glucocorticoid mediated regulation of prostaglandin synthase gene in
cardiovascular diseases. Mukesh also was a faculty member at Georgetown
University where he pioneered research in the field of tracheobronchial mucin,
which is a glycoprotein that is abnormally expressed in lung cancer. He was the
PI of a competitive grant. He was the first to define the structure of the
promoter of the tracheobronchial mucin gene and its regulation, which led to
development of gene therapy approaches to airways diseases. In 1997, he joined
NIH’s National Institute of Allergy and Infectious Diseases and extended his
work in the field of T-cell receptor biology and retroviral-based gene therapy
of cancer. Subsequently, he joined National Cancer Institute in 1999. He has
published 84 research articles (49 as primary author) in international journals
such as PNAS, Virology, Lancet Oncology, Nature Reviews: Cancer, Molecular and
General Genetics, Cancer Epidemiology, Biomarkers and Prevention, and has edited
two books, Molecular Signatures of Infectious Agents in Cancer and Epigenetics
and Cancer Prevention. He serves on the Editorial Board of the journal “Applied
Genomics and Proteomics.”
PUBLICATIONS:
Dr. Verma has published 84 research articles in:
- PNAS
- Virology
- Lancet Oncology
- Nature Reviews: Cancer
- Molecular and General Genetics
- Cancer Epidemiology, Biomarkers and Prevention
Some of his selected publications are:
Verma, M. and Davidson,
E.A. (1993). Molecular cloning and sequencing of a canine tracheo-bronchial
mucin cDNA containing a cysteine rich domain. Proc. Natl. Acad. Sc. USA. 90:
7144-7148.
Verma, M., Olnes, M.J., Kurl, R.N., and Davidson, E.A. (1995).
Primary structure of the canine U1 snRNA. Gene. 154: 255-257.
Verma, M and
Davidson, E.A. (1996). Transcriptional regulation of tracheo-bronchial mucin
gene by ethanol. Gene. 189: 9-12.
Srivastava, S.K., Verma, M., and Henson,
D. (2001). Biomarkers for early detection of colon cancer. Clinical Cancer
Research. 7: 1118-1126.
Verma, M. (Editor). (2002). Molecular Signatures of
Infectious Agents in Cancer. IOS Press. Amsterdam. Netherland.
Verma, M. and
Srivastava, S. (2002). Epigenetics in Cancer: Implications for Early Detection
and Prevention. Lancet Oncology. 3, 755-763.
Verma, M., Dunn, B., and Umar,
A. (2003) (Ed.). Epigenetics in cancer prevention. Annals of New York Academy of
Sciences. NY.
Verma, M., Kagan, J., Sidransky, S., and Srivasatava, S.
(2003). Proteomic analysis of the cancer cell mitochondria. Nature Reviews:
Cancer 3, 789-795.
Verma, M., Maruvada, P., and Srivastava, S. (2004).
Epigenetics and cancer. In: Critical Reviews in Clinical Sciences. 41: 585-607.
Verma, M. (2005). Pancreatic cancer epidemiology. Tech. Cancer Res.
Treatment. 4: 295-302.
Verma, M., Seminara, D., Arena, J. F., John, C.,
Iwamoto, K., and Hartmuller, V. (2006). Genetic and epigenetic biomarkers in
cancer: improving diagnosis and risk assessment. Molecular Diagnosis and Therapy
10: 1-15.
************************************************************************************
WORK PROFILE:
- Presently at Analytic Epidemiology Research Branch (AERB)
- Was Program Director in Division of Cancer Prevention (DCP)
of National Cancer Institute (NCI)
- Was Coordinator of DCP's Small Business Programs
- Served as Project Officer for an Inter Agency Agreement with
Centers for Disease Control and Prevention(CDC)
- Was in National Institute of Allergy and Infectious Diseases
of National Institute of Health (NIH)
- Was a faculty member at Georgetown University
------------------------------------------------------------------------10:19 26-09-2006
RESEARCH INCLUDE:
- Provide directions in the areas of Biomarkers, early
detection, risk management and prevention of cancer
- Developed concepts on exfoliated cells and circulating DNA
and their application in cancer detection and risk assessment.
- Demonstrated Glucocorticoid mediated regulation of
prostaglandin synthase gene in cardiovascular diseases
- Pioneered research in the field of tracheobronchial mucin
leading to development of gene therapy approaches in airways diseases
- Worked in the field of T-cell receptor biology and
retroviral-based gene therapy of cancer
- Serves on the editorial board of " Applied Genomics and
Proteomics" journal.
BOOKS EDITED:
- Molecular Signatures of Infectious Agents in Cancer
- Epigenetics and Cancer Prevention
*******************************************************************************************************************************